- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04441346
Frequency and Risk Factors of Congestive Heart Failure in Dialysis Patients
Frequency and Risk Factors of Congestive Heart Failure in Dialysis Patients Attending Assiut University Hosptial
This study aims :
To assess the frequency of heart failure in patients with end-stage renal disease on regular dialysis.
To identify the risk factors of heart failure in patients with end-stage renal disease.
To assess the impact of duration of dialysis on heart failure and its prognosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Heart Failure is defined as a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill or eject blood with diagnosis relying on clinical examination and associated with significant mortality and morbidity. Congestive heart failure (CHF) is a cardiovascular complication in which the heart becomes unable to supply a sufficient amount of blood to meet the metabolic requirements and fulfill the body's oxygen demand.
CHF is an independent risk factor for early mortality in ESRD patients. More than half of all deaths among ESRD patients are due to cardiovascular disease (CVD). Cardiovascular changes secondary to renal dysfunction, including fluid overload, uremic cardiomyopathy, secondary hyperparathyroidism, anemia, altered lipid metabolism, and accumulation of gut microbiota-derived uremic toxins like trimethylamine N-oxidase (TMAO), contribute to the high risk for CVD in the ESRD population. Also, conventional hemodialysis (HD) itself poses myocardial stress and injury to the already compromised cardiovascular system in uremic patients.
The characteristics of cardiovascular dysfunction observed in dialysis patients are distinct from those noted in the general population. Although traditional cardiovascular risk factors in patients with end-stage renal disease (ESRD) are highly prevalent, they play only a partial role in the excessive cardiovascular morbidity and mortality of this population. The paradoxical association between several traditional risk factors, such as body mass index, blood pressure (BP) and serum cholesterol, and mortality have been previously reported.
In the ESRD population, Hemodialysis (HD) contributes itself to the development of CHF with sustained fluid overload a major cause of hypertension, heart failure, and mortality in patients with ESRD. We postulate that repeated myocardial micro-injury during maintenance hemodialysis may lead to irreversible cardiac dysfunction and subsequent heart failure and death in some patients.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Esraa Galal
- Phone Number: 0201094424433
- Email: esraagalal.eg@gmail.com
Study Contact Backup
- Name: Dina Ali, DR
- Phone Number: 0201063040703
- Email: dinaalihamad@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ESRD patient on regular hemodialysis
Exclusion Criteria:
- AKI patients on HD
- Patients discontinued therapy during the study period will be excluded.
- Patients with structural heart disease (congenital or valvular heart disease)
- Patients with obstructive or restrictive lung diseases.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patients with recent hemodialysis(less than 6 month
|
test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
|
patients on hemodialysis more than 6 months and l
|
test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
|
patients on hemodialysis more than 5 years
|
test that uses high frequency sound waves (ultrasound) to make pictures of your heart.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
risk factors of CHF in hemodialysis patients
Time Frame: July 2020 to July 2021
|
identification of risk factors using demographic and disease characteristics of the patient as age, gender, systolic and diastolic blood pressure, dialysis access, frequency and duration of HD
|
July 2020 to July 2021
|
incidence of CHF in hemodialysis patients
Time Frame: July 2020 to July 2021
|
identification of CHF in ESRD patients using echocardiography
|
July 2020 to July 2021
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
impact of duration of dialysis on heart failure
Time Frame: July 2020 to July 2021
|
determine the extent of CHF in relation to duration of dialysis
|
July 2020 to July 2021
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHF in Dialysis patients
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congestive Heart Failure
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
ELA Medical, Inc.Approved for marketing
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
Clinical Trials on Echocardiography
-
Kang YanRecruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingNon-valvular Atrial Fibrillation | Embolic StrokeChina
-
Assiut UniversityUnknownCORONARY ARTERY BYPASSEgypt
-
Assiut UniversityUnknownMyocardial Infarction | Left Ventricular Dysfunction | Echocardiography 2DEgypt
-
Milton S. Hershey Medical CenterCompletedEchocardiography, Transesophageal | Ventricular Function, RightUnited States
-
Weill Medical College of Cornell UniversityWithdrawn3D Transesophageal and Transthoracic EchocardiogramUnited States
-
Assiut UniversityNot yet recruiting
-
Assiut UniversityNot yet recruiting
-
Ruijin HospitalRecruitingDiabetes Mellitus, Type 2 | Chronic Total Occlusion of Coronary ArteryChina
-
University Medical Center GroningenZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingHeart Failure | Ventricular Dysfunction | Cardiotoxicity | Neoplasm, BreastNetherlands